Goserelin

• Progression under Olaparib: a randomized phaSE II trIal with docetaxel or carboplatin-docetaxel DOublet in mCRPC patieNts Pending
  2023-503676-25-01 Phase II 1 country Azienda Provinciale Per I Servizi Sanitari
• A clinical study on SHR3680 combined with androgen deprived therapy (ADT) versus Bicalutamide combined with ADT in treatment of prostate can… Pending
  2024-515194-10-00 Phase III 3 countries Jiangsu Hengrui Pharmaceuticals Co. Ltd.
• Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Pending
  2024-519655-28-00 Phase III 7 countries Unicancer
• Impact of EXercise on quality of life of early breast cancer patients on treatment with adjuvant Aromatase Inhibitors with or without CDK4/6… Pending
  2025-522848-40-00 Phase IV 1 country Fundacion Grupo Espanol De Investigacion En Cancer De Mama
• Study of GVV858 as a single agent or in combination with endocrine therapy in patients with HR+/HER2- breast cancer and other advanced solid… Recruiting
  2025-521911-38-00 Phase I (FiH) 6 countries Novartis Pharma AG
• NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting
  2025-520979-13-00 Phase III 5 countries Unicancer
• Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors Recruiting
  2024-517281-42-00 Phase I (FiH) 6 countries Novartis Pharma AG
• Artificial Intelligence driven personalisation of radiotherapy and concomitant androgen deprivation therapy for prostate cancer patients Recruiting
  2024-510707-11-00 Phase II 1 country Linac-Pet Scan Opco Limited
• Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag… Recruiting
  2023-507482-26-00 Phase III 4 countries Unicancer
• The RED FLASH study Recruiting
  2023-507847-13-00 Phase III 1 country Reinier de Graaf Groep
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 Phase III 16 countries AstraZeneca AB
• A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer Recruiting
  2022-501504-95-00 Phase II 3 countries Karolinska University Hospital
• A trial to learn more about the effects of ribociclib taken with endocrine therapy in patients with early breast cancer. Ended
  2022-503001-38-01 Phase III 2 countries Novartis Pharma AG
• Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-… Ended
  2024-513540-29-00 Phase III 5 countries Alliance Foundation Trials LLC
• A Phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing pep… Ended
  2023-506717-21-00 Phase I/II 6 countries Novartis Pharma AG
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended
  2022-501024-20-00 Phase III 14 countries Astrazeneca AB
• A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea… Ended
  2023-510357-42-00 Phase III 10 countries Novartis Pharma AG
• A research study to compare the standard treatment and the study drug (degarelix) in combination with radiotherapy in patients with high-ris… Ended
  2024-513450-30-00 Phase III 3 countries Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europ…
• Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) me… Ended
  2022-502372-22-01 Phase II 1 country Unicancer
• Study assessing the efficacy and safety of alpelisib plus fulvestrant or letrozole, based on prior endocrine therapy, in patients with PIK3C… Ended
  2023-509167-24-00 Phase II 2 countries Novartis Pharma AG

Showing 1–20 of 20 trials